Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults Pharmaceutical Investing
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS APPH, BMY, EAR, HYZN INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits Pharmaceutical Investing
Presenting Sponsor Boosh To Introduce New Shelf Stable Plant-Based Mac & Cheese at Planted Expo Company News
Cardiol Therapeutics Receives Health Canada Approval for Phase II Clinical Trial of CardiolRx for Acute Myocarditis Pharmaceutical Investing
Bristol Myers Squibb Announces Earnings Call Time Change; Third Quarter 2021 Earnings Call to Occur on October 27, 2021 at 10 a.m. Pharmaceutical Investing
TCR² Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo® and Yervoy® in Mesothelin-Expressing Solid Tumors Pharmaceutical Investing
BMY, HNST, HYZN, SAM INVESTOR ALERT BY CLAIMSFILER: Pending Lead Plaintiff Deadline in Class Action Lawsuits Pharmaceutical Investing
BRISTOL-MYERS CVR INVESTORS: December 6, 2021 Filing Deadline in Class Action - Contact Lieff Cabraser Pharmaceutical Investing
Gilead Presents Long-Term Switch Data Reinforcing Biktarvy® as a Treatment Option for a Broad Range of People Living With HIV Biotech Investing
